ClinicalTrials.gg
CompletedNCT02923375Updated Aug 11, 2020

A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease

A Phase 1 interventional study of Mesenchymoangioblast-derived mesenchymal stem cells in Graft vs Host Disease, sponsored by Cynata Therapeutics Limited. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by Cynata Therapeutics Limited · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Graft vs Host Disease with a site in United Kingdom — 1 open to participants now, 2 under way, none of them phase 3. Graft vs Host Disease · United Kingdom.

Enrollment
22nd of 25
16 · median 63
Started
2017
with 5 others
Phase 1
2 of 27
none open now
Registered
17th of 27
by date
Lead sponsor
1 of 27
Cynata Therapeutics Limited

Among the 27 studies in Graft vs Host Disease with a site in United Kingdom, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2017, is one of 2 in phase 1, and was the 17th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

1 of the 27 studies in Graft vs Host Disease with a site in United Kingdom is open now. Recruiting first, the newest first:

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Graft vs Host Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and efficacy of two infusions of CYP-001 in adults with steroid-resistant GvHD.

Read the detailed description

This is a multi-centre, open label, dose escalation study to assess the safety, tolerability and efficacy of two infusions of CYP-001, in adults who have steroid-resistant GvHD.

Participants will receive standard of care treatment throughout the study, according to local procedures. The first eight participants will be enrolled in Cohort A and receive a CYP-001 dose of 1 million cells per kg, up to a maximum dose of 100 million cells, on Day 0 and Day 7. Subject to a safety review of data from Cohort A, an additional eight participants will be enrolled into Cohort B and receive a CYP-001 dose of 2 million cells/kg, up to a maximum dose of 200 million cells, on Day 0 and Day 7. The primary evaluation period concludes for each participant 100 days after the first dose of CYP-001. Participants will have study visits on Days 0, 3, 7, 14, 21, 28, 60 and 100. Subsequently, participants will enter a long term follow-up period, which concludes 2 years after the first dose of CYP-001.

03

Conditions studied

  • Graft vs Host Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis using consensus grading with -resistant Grade II-IV acute GvHD, after a haematopoietic stem cell transplant for a haematological disorder.
  • of at least one month.
  • Agree to have follow-up data collected for two years after their initial dose of CYP-001 (under a separate protocol).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding or plan to become pregnant within three months of receiving their last dose of CYP-001.
  • Have received any research agent within 30 days or five half-lives (whichever is longer) prior to the first dose of IMP.
  • Known or suspected current alcohol or substance abuse problem.
  • Progressive or relapsing haematological , a current solid tumour, or previous malignant solid tumour that is likely to recur during the period of the study (with the exception of a past history of basal or squamous cell carcinomas).
  • Heart failure ( Functional Class II-IV) and/or pulmonary failure.
  • Haemodynamically unstable and/or at high risk of cardiovascular events.
  • Terminal organ failure.
  • Meningitis, pneumonia with hypoxemia, or another severe or uncontrolled systemic infection, which in the opinion of the investigator is likely to impact on the ability of the patient to participate in the trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Cohort A

    Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)

    Biological: Mesenchymoangioblast-derived mesenchymal stem cells

  • Experimental
    Cohort B

    Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)

    Biological: Mesenchymoangioblast-derived mesenchymal stem cells

Interventions

  • BiologicaliPSC-derived MSCs CYP-001Studies of iPSC-derived MSCs CYP-001iPSC-derived MSCs CYP-001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.

    Also known as: CYP-001

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent adverse events [safety and tolerability]

    Safety

    Time frame: 28 days

  2. Incidence and severity of serious adverse events deemed possibly related to CYP-001 [safety and tolerability]

    Safety

    Time frame: 100 days

Secondary outcomes

  1. Complete Response by Day 28

    Proportion of participants who show a Complete Response (absence of any signs or symptoms of GvHD) by Day 28

    Time frame: 28 days

  2. Partial Response by Day 28

    Proportion of participants who show a Partial Response (improvement in the severity of GvHD by at least one grade compared to baseline) by Day 28

    Time frame: 28 days

  3. Overall Survival at Day 28

    Proportion of participants who survive until Day 28

    Time frame: 28 days

  4. Complete Response by Day 100

    Proportion of participants who show a Complete Response by Day 100

    Time frame: 100 days

  5. Partial Response by Day 100

    Proportion of participants who show a Partial Response by Day 100

    Time frame: 100 days

  6. Overall Survival at Day 100

    Proportion of participants who survive until Day 100

    Time frame: 100 days

07

Study locations

7 sites
  • Sydney Local Health District
    Sydney, New South Wales, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia, Australia
  • NHS Foundation Trust
    Bristol, United Kingdom
  • NHS Trust
    Leeds, United Kingdom
  • NHS Foundation Trust
    Liverpool, United Kingdom
  • NHS Foundation Trust
    Manchester, United Kingdom
  • NHS Foundation Trust
    Nottingham, United Kingdom
08

References and documents

Publications

  • Bloor AJC, Patel A, Griffin JE, Gilleece MH, Radia R, Yeung DT, Drier D, Larson LS, Uenishi GI, Hei D, Kelly K, Slukvin I, Rasko JEJ. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat Med. 2020 Nov;26(11):1720-1725. doi: 10.1038/s41591-020-1050-x. Epub 2020 Sep 14. PubMed 32929265 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Aug 2018, 17 months.

Of 49 phase 1 interventional studies under Graft vs Host Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2016
First posted
Oct 4, 2016
StartActual
Mar 1, 2017
Primary completionActual
Aug 28, 2018
CompletionActual
Jun 30, 2020
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02923375
Lead sponsor
Cynata Therapeutics Limited
Responsible party
Sponsor
First posted
Oct 4, 2016
Start date
Mar 1, 2017
Primary completion
Aug 28, 2018
Completion
Jun 30, 2020
Last update
Aug 11, 2020

Study contacts

Kilian Kelly, PhD
study director · Cynata Therapeutics Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: iPSC-derived MSCs CYP-001

Start the discussion